Marinus Pharmaceuticals Inc (MRNS)

01:44 AM

Immedica to buy Marinus Pharmaceuticals for $151m - Yahoo Finance

01:44 AM

Dec 30, 2024

Immedica to buy rare disease drugmaker Marinus for $151 million - Crain's Chicago Business

Dec 30, 2024

Dec 30, 2024

Marinus Pharmaceuticals ends agreements with Orion Corporation By Investing.com - Investing.com Nigeria

Dec 30, 2024

Dec 30, 2024

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Marinus Pharmaceuticals, Inc.MRNS - The Malaysian Reserve

Dec 30, 2024

Dec 30, 2024

Marinus Pharmaceuticals ends agreements with Orion Corporation - Investing.com India

Dec 30, 2024

Dec 30, 2024

Immedica Pharma AB entered into an agreement to acquire Marinus Pharmaceuticals, Inc.. - Marketscreener.com

Dec 30, 2024

Dec 30, 2024

Immedica to Acquire Marinus Pharmaceuticals in $151 Million Deal; Shares Surge 43% - Yahoo Finance

Dec 30, 2024

Dec 30, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MRNS, VCSA, MHLD on Behalf of Shareholders - Stockhouse Publishing

Dec 30, 2024

Dec 30, 2024

Marinus Pharma Agrees To $151 Million Acquisition By Immedica: Shares Surge Over 40% - Benzinga

Dec 30, 2024

Dec 30, 2024

Shareholder Alert: Ademi LLP Investigates Whether Marinus Pharmaceuticals, Inc. Is Obtaining a Fair Price for Its Public Shareholders - Business Wire

Dec 30, 2024

Dec 30, 2024

MRNS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Marinus Pharmaceuticals, Inc. Is Fair to Shareholders - Business Wire

Dec 30, 2024

Dec 30, 2024

Marinus Therapeutics to be acquired by Swedish company in $151M deal - Philadelphia Business Journal

Dec 30, 2024

Dec 30, 2024

Marinus Pharma to Be Acquired by Immedica in $30 Million Deal - MarketWatch

Dec 30, 2024

Dec 30, 2024

Marinus Pharmaceuticals Merges with Immedica Pharma AB - TipRanks

Dec 30, 2024

Dec 30, 2024

Marinus Ends Agreements Amid Strategic Review - TipRanks

Dec 30, 2024

Dec 30, 2024

Immedica to acquire Marinus Pharmaceuticals for $151 million - Investing.com

Dec 30, 2024

Dec 30, 2024

Orion and Marinus terminate agreement for ganaxolone in Europe - The Manila Times

Dec 30, 2024

Dec 30, 2024

Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc. - Milton Daily Standard

Dec 30, 2024

Dec 28, 2024

Marinus Pharmaceuticals (NASDAQ:MRNS) Coverage Initiated at StockNews.com - Defense World

Dec 28, 2024

Dec 26, 2024

Marinus Pharmaceuticals Approves Senior Management Retention and Change in Control Severance PlansOn December 17, 2024, Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) announced the approval of a retention plan for senior management and an a - Defense World

Dec 26, 2024

Dec 23, 2024

Marinus Unveils Management Retention and Severance Plans - TipRanks

Dec 23, 2024

Dec 20, 2024

Marinus Pharma stock hits 52-week low at $0.23 By Investing.com - Investing.com Nigeria

Dec 20, 2024

Dec 20, 2024

Marinus Pharma stock hits 52-week low at $0.23 - Investing.com India

Dec 20, 2024

Dec 16, 2024

Layoff Tracker: Editas Will Cut 60% of Staff - BioSpace

Dec 16, 2024

Dec 16, 2024

Marinus Pharmaceuticals' SWOT analysis: epilepsy drug maker's stock faces pivotal moment - Investing.com

Dec 16, 2024

Dec 14, 2024

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Receives Average Recommendation of “Hold” from Brokerages - Defense World

Dec 14, 2024

Dec 13, 2024

Marinus Pharma stock hits 52-week low at $0.26 amid steep decline - Investing.com

Dec 13, 2024

Dec 13, 2024

Marinus Pharma stock hits 52-week low at $0.26 amid steep decline By Investing.com - Investing.com South Africa

Dec 13, 2024

Dec 12, 2024

Marinus Pharmaceuticals (NASDAQ:MRNS) Earns Hold Rating from Analysts at StockNews.com - Defense World

Dec 12, 2024

Dec 10, 2024

Marinus Pharmaceuticals faces Nasdaq delisting risk - Investing.com

Dec 10, 2024

Dec 10, 2024

Marinus Pharmaceuticals faces Nasdaq delisting risk By Investing.com - Investing.com Nigeria

Dec 10, 2024

Dec 04, 2024

Marinus Pharmaceuticals' SWOT analysis: stock faces challenges amid pipeline setbacks By Investing.com - Investing.com South Africa

Dec 04, 2024

Dec 03, 2024

Marinus Pharmaceuticals' SWOT analysis: stock faces challenges amid pipeline setbacks - Investing.com India

Dec 03, 2024

Dec 02, 2024

MRNS (Marinus Pharmaceuticals) Enterprise Value : $31.67 Mil (As of Dec. 02, 2024) - GuruFocus.com

Dec 02, 2024

Dec 01, 2024

MRNS (Marinus Pharmaceuticals) Revenue per Share : $0.55 (TTM As of Sep. 2024) - GuruFocus.com

Dec 01, 2024

Nov 29, 2024

Shareholders that lost money on Marinus Pharmaceuticals, Inc.(MR - GuruFocus.com

Nov 29, 2024

Nov 28, 2024

MRNS (Marinus Pharmaceuticals) Net Income : $-140.49 Mil (TTM As of Sep. 2024) - GuruFocus.com

Nov 28, 2024

Nov 26, 2024

Marinus Pharmaceuticals (LTS:0JYL) COGS-to-Revenue : 0.08 (As of Sep. 2024) - GuruFocus.com

Nov 26, 2024

Nov 26, 2024

Levi & Korsinsky Notifies Marinus Pharmaceuticals, Inc. Investor - GuruFocus.com

Nov 26, 2024

Nov 26, 2024

CDKL5 Deficiency Disorder Market Revenue to Expand Significantly by 2034, States DelveInsight Report | Marinus Pharma, Takeda, Zogenix, Inc., UCB, Ultragenyx Pharma - The Globe and Mail

Nov 26, 2024

Nov 26, 2024

CDKL5 Deficiency Disorder Market Revenue to Expand - openPR

Nov 26, 2024

Nov 20, 2024

Marinus Pharmaceuticals Reports Q3 2024 Financial Results and Strategic Developments - MSN

Nov 20, 2024

Nov 17, 2024

Marinus Pharmaceuticals Board Members Resign, Prompting Director ReductionOn November 14, 2024, Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) experienced a significant change within its Board of Directors. Charles Austin, Saraswathy V. Nochur, P - Defense World

Nov 17, 2024